In summary, we determined that targeting FAM111B favours the inhibition of HCC progression by promoting RANBP9-induced MFN2 ubiquitinated degeneration and that sGLNP successfully delivered shFAM111B to inhibit HCC progression and enhance the effect of lenvatinib for HCC treatment. This evidence concerns the gene MFN2 and hepatocellular carcinoma.